5 Key Takeaways

• 1

  Cell and gene therapies have demonstrated potential to transform medicine, but broad access remains challenging.

• 2

  The discussion identifies complex manufacturing, fragmented data systems, regulatory requirements, limited care sites, and uncertain reimbursement as potential bottlenecks.

• 3

  Experts from across the cell and gene therapy ecosystem discuss where the industry should focus its efforts.

• 4

  The roundtable considers whether the sector is addressing the right problems and where greater collaboration is needed.

• 5

  Participants discuss how AI and other emerging technologies could help address barriers between therapeutic innovation and patient access.